Repligen (NASDAQ:RGEN) Price Target Lowered to $185.00 at UBS Group

Repligen (NASDAQ:RGEN) had its target price reduced by UBS Group from $205.00 to $185.00 in a report issued on Wednesday morning, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

Several other equities analysts have also issued reports on the stock. Stephens reaffirmed an overweight rating and issued a $170.00 price target on shares of Repligen in a report on Tuesday. JPMorgan Chase & Co. cut their price target on shares of Repligen from $230.00 to $200.00 and set an overweight rating on the stock in a report on Thursday, May 2nd. Royal Bank of Canada reaffirmed an outperform rating and issued a $190.00 price target on shares of Repligen in a report on Wednesday. Deutsche Bank Aktiengesellschaft raised shares of Repligen from a hold rating to a buy rating and cut their price target for the stock from $180.00 to $155.00 in a report on Wednesday, June 26th. Finally, Guggenheim initiated coverage on shares of Repligen in a report on Tuesday, June 18th. They issued a neutral rating on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, Repligen presently has an average rating of Moderate Buy and a consensus target price of $190.88.

Repligen Stock Performance

Shares of RGEN stock opened at $167.35 on Wednesday. The firm has a market cap of $9.35 billion, a price-to-earnings ratio of 669.40, a PEG ratio of 5.37 and a beta of 0.95. The company’s 50 day moving average is $134.71 and its 200 day moving average is $166.13. The company has a quick ratio of 5.24, a current ratio of 6.35 and a debt-to-equity ratio of 0.26. Repligen has a 52-week low of $110.45 and a 52-week high of $211.13.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.33. The company had revenue of $154.07 million for the quarter, compared to analyst estimates of $154.11 million. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. Repligen’s revenue was down 3.2% compared to the same quarter last year. During the same period last year, the company posted $0.53 earnings per share. On average, sell-side analysts anticipate that Repligen will post 1.46 EPS for the current fiscal year.

Insider Activity at Repligen

In related news, CEO Anthony Hunt sold 20,072 shares of the business’s stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the completion of the transaction, the chief executive officer now directly owns 163,177 shares in the company, valued at $27,456,162.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Martin D. Madaus acquired 1,615 shares of the firm’s stock in a transaction on Friday, June 14th. The stock was acquired at an average price of $124.94 per share, for a total transaction of $201,778.10. Following the completion of the transaction, the director now owns 4,613 shares in the company, valued at approximately $576,348.22. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Anthony Hunt sold 20,072 shares of the company’s stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the completion of the transaction, the chief executive officer now owns 163,177 shares of the company’s stock, valued at approximately $27,456,162.02. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Picton Mahoney Asset Management raised its position in shares of Repligen by 32.7% in the second quarter. Picton Mahoney Asset Management now owns 650 shares of the biotechnology company’s stock worth $82,000 after acquiring an additional 160 shares during the period. Van ECK Associates Corp raised its position in shares of Repligen by 0.9% in the second quarter. Van ECK Associates Corp now owns 45,185 shares of the biotechnology company’s stock worth $5,696,000 after acquiring an additional 404 shares during the period. Rothschild Investment LLC purchased a new stake in shares of Repligen during the second quarter worth about $57,000. Legacy Advisors LLC increased its stake in shares of Repligen by 30.5% during the second quarter. Legacy Advisors LLC now owns 5,732 shares of the biotechnology company’s stock worth $723,000 after purchasing an additional 1,338 shares in the last quarter. Finally, International Assets Investment Management LLC purchased a new stake in shares of Repligen during the second quarter worth about $33,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.